(Q37001375)

17 August 2017

1 reference

title

CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? (English)

1 reference

17 August 2017

Laurent Antoni

1

1 reference

17 August 2017

Nayanta Sodha

series ordinal

2

1 reference

17 August 2017

Ian Collins

series ordinal

3

1 reference

17 August 2017

Michelle D Garrett

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

Nature Reviews Cancer

1 reference

17 August 2017

7

1 reference

17 August 2017

925-936

1 reference

17 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2251

17 August 2017

0 references

cites work

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

1 reference

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

31 March 2020

1 reference

Screening hCHK2 for Mutations

31 March 2020

1 reference

The CHEK2 gene and inherited breast cancer susceptibility

31 March 2020

1 reference

A novel founder CHEK2 mutation is associated with increased prostate cancer risk.

31 March 2020

1 reference

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

31 March 2020

1 reference

Increasing evidence that germline mutations inCHEK2 do not cause Li-Fraumeni syndrome

31 March 2020

1 reference

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

31 March 2020

1 reference

Targeting the double-strand DNA break repair pathway as a therapeutic strategy

31 March 2020

1 reference

The DNA damage response: putting checkpoints in perspective

31 March 2020

1 reference

Targeting chk2 kinase: molecular interaction maps and therapeutic rationale

31 March 2020

1 reference

hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response

31 March 2020

1 reference

Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair

31 March 2020

1 reference

Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.

31 March 2020

1 reference

Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining

31 March 2020

1 reference

Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes

31 March 2020

1 reference

A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase

31 March 2020

1 reference

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway

31 March 2020

1 reference

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase

31 March 2020

1 reference

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

31 March 2020

1 reference

Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.

31 March 2020

1 reference

Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription

31 March 2020

1 reference

Activation of the ATM kinase by ionizing radiation and phosphorylation of p53

31 March 2020

1 reference

Enhanced phosphorylation of p53 by ATM in response to DNA damage

31 March 2020

1 reference

Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint

31 March 2020

1 reference

DNA-dependent acetylation of p53 by the transcription coactivator p300.

31 March 2020

1 reference

p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation.

31 March 2020

1 reference

ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage

31 March 2020

1 reference

Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3.

31 March 2020

1 reference

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

31 March 2020

1 reference

Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner

31 March 2020

1 reference

Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response

31 March 2020

1 reference

DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage

31 March 2020

1 reference

Regulation of CHK2 by DNA-dependent protein kinase

31 March 2020

1 reference

Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells

31 March 2020

1 reference

Chk2 activates E2F-1 in response to DNA damage

31 March 2020

1 reference

Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2.

31 March 2020

1 reference

PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2

31 March 2020

1 reference

Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation

31 March 2020

1 reference

Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody

31 March 2020

1 reference

Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways

31 March 2020

1 reference

The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe

31 March 2020

1 reference

Activated checkpoint kinase 2 provides a survival signal for tumor cells

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

DNA damage checkpoint kinase Chk2 triggers replicative senescence

31 March 2020

1 reference

Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer

31 March 2020

1 reference

p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.

31 March 2020

1 reference

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

31 March 2020

1 reference

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

31 March 2020

1 reference

31 March 2020

1 reference

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

31 March 2020

1 reference

Germline TP53 mutations and Li-Fraumeni syndrome

31 March 2020

1 reference

ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data

31 March 2020

1 reference

Mutation and cancer: statistical study of retinoblastoma

31 March 2020

1 reference

A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li – Fraumeni patients carrying a mutation to the TP53 gene

31 March 2020

1 reference

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

31 March 2020

1 reference

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer

31 March 2020

1 reference

CHEK2 variants associate with hereditary prostate cancer

31 March 2020

1 reference

CHEK2-positive breast cancers in young Polish women

31 March 2020

1 reference

Breast cancer predisposing alleles in Poland

31 March 2020

1 reference

CHEK2 variant I157T may be associated with increased breast cancer risk.

31 March 2020

1 reference

CHEK2 is a multiorgan cancer susceptibility gene

31 March 2020

1 reference

Association of two mutations in theCHEK2 gene with breast cancer

31 March 2020

1 reference

CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors

31 March 2020

1 reference

CHEK2 I157T associates with familial and sporadic colorectal cancer

31 March 2020

1 reference

Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia

31 March 2020

1 reference

Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women

31 March 2020

1 reference

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies

31 March 2020

1 reference

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.

31 March 2020

1 reference

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

31 March 2020

1 reference

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

31 March 2020

1 reference

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline Mutation

31 March 2020

1 reference

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry

31 March 2020

1 reference

Epistatic relationship between the cancer susceptibility genes CHEK2 and p27

31 March 2020

1 reference

Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.

31 March 2020

1 reference

Mutations in CHEK2 associated with prostate cancer risk

31 March 2020

1 reference

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland

31 March 2020

1 reference

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours

31 March 2020

1 reference

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility

31 March 2020

1 reference

Limited relevance of the CHEK2 gene in hereditary breast cancer.

31 March 2020

1 reference

Characterization of tumor-associated Chk2 mutations

31 March 2020

1 reference

Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation

31 March 2020

1 reference

Characterization of CHEK2 mutations in prostate cancer

31 March 2020

1 reference

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals

31 March 2020

1 reference

Homozygosity for aCHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype

31 March 2020

1 reference

Concomitant inactivation of p53 and Chk2 in breast cancer

31 March 2020

1 reference

Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer

31 March 2020

1 reference

The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis

31 March 2020

1 reference

Analysis of CHK2 in patients with myelodysplastic syndromes

31 March 2020

1 reference

Analysis of CHK2 in vulval neoplasia

31 March 2020

1 reference

Mutations of Chk2 in primary hematopoietic neoplasms

31 March 2020

1 reference

Mutation analysis of the CHK2 gene in breast carcinoma and other cancers

31 March 2020

1 reference

CHEK2 mutations in primary glioblastomas.

31 March 2020

1 reference

Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors

31 March 2020

1 reference

Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers

31 March 2020

1 reference

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

31 March 2020

1 reference

CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas

31 March 2020

1 reference

Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer DifferentiateBRCA2-Associated Tumors

31 March 2020

1 reference

Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study.

31 March 2020

1 reference

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment

31 March 2020

1 reference

Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.

31 March 2020

1 reference

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

31 March 2020

1 reference

Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange

31 March 2020

1 reference

Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.

31 March 2020

1 reference

Identification of novel, selective and potent Chk2 inhibitors

31 March 2020

1 reference

Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2

31 March 2020

1 reference

Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles

31 March 2020

1 reference

Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

31 March 2020

1 reference

The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast

31 March 2020

1 reference

A kinase from fission yeast responsible for blocking mitosis in S phase.

31 March 2020

1 reference

31 March 2020

1 reference

Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro

31 March 2020

1 reference

The Chk2 tumor suppressor is not required for p53 responses in human cancer cells

31 March 2020

1 reference

Questioning the role of checkpoint kinase 2 in the p53 DNA damage response

31 March 2020

1 reference

Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1.

31 March 2020

1 reference

ATR dependent activation of Chk2.

31 March 2020

1 reference

Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage

31 March 2020

1 reference

TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68.

31 March 2020

1 reference

The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation

31 March 2020

1 reference

Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain

31 March 2020

1 reference

Chk2 activation and phosphorylation-dependent oligomerization

31 March 2020

1 reference

Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase

31 March 2020

1 reference

The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase

31 March 2020

1 reference

Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation

31 March 2020

1 reference

Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis

31 March 2020

1 reference

DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues.

31 March 2020

1 reference

Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase.

31 March 2020

1 reference

Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456.

31 March 2020

1 reference

Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine

31 March 2020

1 reference

Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2

31 March 2020

1 reference

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2251

1 reference

17 August 2017

1 reference